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Abstract
Background: Use of a risk of bias (ROB) tool has been encouraged and advocated to reviewers writing systematic reviews
(SRs) and meta-analyses (MAs). Selective outcome reporting and other sources of bias are included in the Cochrane ROB
tool. It is important to know how this specific tool for assessing ROB has been applied since its release. Our objectives were
to evaluate whether and to what extent the new Cochrane ROB tool has been used in Chinese journal papers of
acupuncture.
Methods: We searched CBM, TCM database, CJFD, CSJD, and the Wanfang Database from inception to March 2011. Two
reviewers independently selected SRs that primarily focused on acupuncture and moxibustion, from which the data was
extracted and analyzed.
Results: A total of 836 SRs were identified from the search, of which, 105 were included and four are awaiting assessment.
Thirty-six of the 105 SRs were published before release of the Cochrane ROB tool (up to 2009). Most used the Cochrane
Handbook 4.2 or Jadad’s scale for risk or quality assessment. From 2009 to March 2011 69 SRs were identified. While ‘‘risk of
bias’’ was reported for approximately two-thirds of SRs, only two SRs mentioned use of a ‘‘risk of bias tool’’ in their
assessment. Only 5.8% (4/69) of reviews reported information on all six domains which are involved in the ROB tool. A risk of
bias graph/summary figure was provided in 2.9% (2/69) of reviews. Most SRs gave information about sequence generation,
allocation concealment, blindness, and incomplete outcome data, however, few reviews (5.8%; 4/69) described selective
reporting or other potential sources of bias.
Conclusions: The Cochrane ‘‘risk of bias’’ tool has not been used in all SRs/MAs of acupuncture published in Chinese
Journals after 2008. When the ROB tool was used, reporting of relevant information was often incomplete.
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Introduction
Assessment of internal validity, risk of bias, or methodological
quality of studies included in systematic reviews (SRs) and meta-
analyses (MAs) is a very important step in identifying limitations of
individual studies. Randomized controlled trials (RCTs) are often
included as the study type for SRs of interventions.
Since the 1980s, numerous tools involving scales and checklists
have been developed for assessing the methodological quality of
clinical trials [1], including the Cochrane Collaboration’s ‘‘risk of
bias’’(ROB) tool which was published in2008 [2]. It shows that ‘‘the
ROBtooliscomposedoftwoparts,‘description’and‘judgment’.For
parallel group trials, it addresses six specific domains: sequence
generation, allocation concealment, blinding, incomplete outcome
data, selective outcome reporting, and other sources of bias. In these
six domains, the judgments of ‘Yes’, ‘No’, or ‘Unclear’ indicates ‘low
risk of bias’, ‘high risk of bias’, and ‘uncertain risk of bias’,
respectively’’ [2]. As an essential guide to writing a Cochrane SRs,
use of the ROB tool has been encouraged and advocated [2].
Moreover, authors are encouraged to use the latest version, which is
currently Handbook 5.1.0 [updated March 2011].
The ROB tool continues to be recommended and disseminated
by the Cochrane Collaboration and its sub-centers in different
countries. In determining the effect of the ROB tool, it is very
important to know how effectively it has been applied. Accordingly,
weevaluatewhetherandtowhatextenttheCochraneROBtoolhas
been used in SRs of acupuncture published in Chinese journals.
Methods
The protocol of this study was written in Chinese which has not
published.
Inclusion Criteria
SRs or MAs of acupuncture/acupressure and moxibustion
published on Chinese journals. We included studies that described
their methods and results in detail.
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SRs and MAs primarily focused on the other traditional
Chinese medicine (TCM) (herbal medicine, massage, etc) rather
than acupuncture.
Search Strategy (Text S1)
Five databases (Chinese Biomedicine Literature Database
(CBM), Traditional Chinese Medicine database (TCM database),
Chinese Journal Full-text Database (CJFD), Chinese Scientific
Journal Full-text Database (CSJD), and Wanfang Database) were
systematically searched from inception to March 2011. The main
search terms were as follows: ‘‘systematic review’’, ‘‘meta-analysis’’,
‘‘acupuncture’’, ‘‘needling’’, ‘‘ear acupuncture’’, ‘‘ electroacupunc-
ture’’, ‘‘electro-acupuncture’’, ‘‘acupuncture points’’, ‘‘acupres-
sure’’, ‘‘moxibustion’’, and ‘‘acupoint’’.
Screening
Two reviewers (Yongteng XU and Huaili JIANG) indepen-
dently screened the title and abstract of each record. Full texts of
potentially included articles were further assessed. Disagreements
were resolved by discussion.
Data Extraction and Analysis
Data about general characteristics and ‘‘risk of bias’’ were
independently extracted by two reviewers (Junjie DAI and Rui
ZHANG). Discrepancies were resolved through discussion or
settled by the third principal investigator (Yali LIU). Since the
ROB tool was first published in February 2008 (Cochrane
handbook 5.0.0) [3], we assessed the use of the ROB tool only
in those reviews published since 2009.
Data was extracted into a standardized form by trained
extractors. The forms was composed of two parts: (1) General
information: publication, type of included studies, funding etc, and
(2) Information related to risk of bias: name and version of
assessment tool, risk of bias graph/summary; randomization
sequence, allocation concealment, blinding, incomplete outcome
data, selective reporting, and other potential sources of bias etc.
Each domain was assessed as ‘yes’ (described in papers), or ‘‘no’’
(not described in papers).
Data was summarized using descriptive statistics (frequency,
percentage). Analysis was carried out with Excel (version Microsoft
Excel 2007; http://office.microsoft.com/zh-cn/) and SPSS soft-
ware (version 13.0; http://www.spss.com).
Results
Search
Our search identified 837 SRs and MAs, of which 675 abstracts
did not meet inclusion criteria. One hundred and sixty-two reviews
were chosen for full text analysis and assessed for inclusion. Full
texts were obtained for 158 reviews; 105 met inclusion criteria and
four are awaiting assessment, as full text was not available
(Figure 1, Text S2). All SRs and MAs were written by Chinese
authors.
Figure 1. Flow chart of articles identified, included and excluded.
doi:10.1371/journal.pone.0028130.g001
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The first systematic review and meta-analysis were published in
2002 and 2003, respectively. Since 2007, the number of SRs and
MAs published annually has increased.
Of the 105 included reviews, 74 and 22 included ‘‘systematic
review’’ and ‘‘meta-analysis’’ in their titles, respectively. However,
there were nine reviews that included ‘‘evidence-based medicine
analysis’’, ‘‘the curative effect comparison appraises’’, and other
phrases in their titles, which were later identified as ‘‘systematic
reviews’’ or ‘‘meta-analyses.’’ All reviews concerned diseases
defined from a western medicine perspective. In total, 15 different
types of diseases were involved, with the majority [24.8% (26/
105)] focused on treatment of diseases of the nervous system.
Diagnostic criteria were reported in 55.2% (58/105) of the
reviews. Of these 58 reviews, 41 reported their diagnostic criteria
based solely on ‘‘Western disease’’ and two reviews reported their
diagnostic criteria based solely on ‘‘TCM syndrome.’’ The
remaining 15 reviews included both ‘‘western disease’’ and
‘‘TCM syndrome’’ diagnostic criteria. Funding was supplied by
at least one funding body for 56.2% (59/105) of reviews. Of these,
98.3% [58/59] were supported by funding from China and only
one was funded by an international foundation (The China
Medical Board, CMB). Most, 94.9% (56/59), failed to provide
declarations of interest, while the remaining three reviews reported
that there were no conflicts of interests.
While most [91.4% (96/105)] SRs and MAs restricted study
design to RCTs, some included controlled clinical trials (CCTs)
[36.2% (38/105)] and quasi-RCTs [13.3% (14/105)]. The
number of trials included in the reviews ranged from three to
203, with a median of 12.7. And the number of included RCTs
ranged from 0 to 67, with a median of 7.
Risk of bias tool (Table 2, 3)
Thirty-six SRs were published during the seven years from 2002
through 2008, and another 69 since 2009. Of the first 36 SRs, one-
third [33.3% (12/36)] used the Jadad scale [4] and one-third
[33.3% (12/36)] applied the Cochrane Handbook. Among the
latter 12 reviews, seven used the Cochrane Handbook 4, and
another five reviews used the Cochrane handbook but failed to
report the exact version used. Most reviews assessed sequence
generation, allocation concealment, blinding, loss of follow-up and
intention-to-treat (ITT) analysis.
Of the 69 SRs published since 2009, 73.91% (51/69) applied
the Cochrane Handbook as an assessment tool. Of these, 18.84%
(13/69) used the Cochrane Handbook 5 and, 36.23% (25/69) used
the Cochrane Handbook 4, and a further thirteen reviews used the
Cochrane handbook but failed to report the version used. The
Jadad scales were used by 57.97% (40/69) and of these, 25 used
both the Cochrane Handbook and the Jadad scale. One review
did not use any quality or ROB assessment for included studies.
Methodological quality and ROB have been used interchangeably
in the SRs and MAs. Most reviews used ‘‘quality assessment’’
rather than ‘‘risk of bias assessment’’ in their methods or results.
Only two reviews specified a ‘‘risk of bias tool’’ as their assessment
tool.
Few [5.8% (4/69)] reviews reported on all six domains of the
Cochrane ROB tool. Most SRs gave information about baseline
similarity; however, only four reviews described other potential
sources of bias and selective reporting bias. A ‘‘risk of bias graph/
summary’’ figure was provided in 2.9% (2/69) of the reviews.
Information about blinding was reported in 68 reviews, but 61
of these failed to report who was blinded in the trials. Most reviews
reported loss of follow-up or ITT analysis, but failed to mention
incomplete outcome data. None of the reviews reported verbatim
quotes in their papers.
Discussion
An increasing number of SRs and MAs of acupuncture have
been published, especially since 2007. In this study, we identified
105 SRs and MAs of acupuncture interventions in Chinese
journals. In addition, there were 36 Cochrane SRs in the
Cochrane Database of Systematic Reviews (CDSR) and 154 SRs
and MAs have been published in international journals that
Table 1. Characteristics of included studies.
Category Characteristic
Number (%) of
n=105
Title Systematic review 74 (70.5)
Meta analyse 22 (20.9)
Others 9 (8.6)
Diagnostic criteria Western medicine (diseases) 41 (39.0)
Traditional medicine 2 (1.9)
Using both disease and syndrome 15 (14.3)
No diagnostic criteria reported 47 (44.8)
funding source The number of reviews with funding source(s) 59 (56.2)
Chinese foundation 58 (98.3*)
International foundation 1 (1.7*)
No declarations of interest 56 (94.9*)
The number of funding sources Median:1 (range: 0–5)
Trial types included RCTs 96
CCT 38
quasi-RCTs 14
*n=59.
doi:10.1371/journal.pone.0028130.t001
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the first to investigate the use of the Cochrane Collaboration’s
ROB tool in the acupuncture field. Although the study was not a
classical systematic review, we tried to report it according to
PRISMA Checklist [14] (Text S3).
We identified other studies that focused on use of the ROB tool.
While most of these studies evaluated the ROB of RCTs and/or
their influence in specific fields, such as dentistry [5], pediatrics
[6], and persistent asthma treatment [7], other studies have
assessed the internal validity of RCTs, inter-rater agreement [8,9],
and concurrent validity [8,9]. Some reviews have contrasted the
ROB tool with other tools, such as the Jadad scale [7,8], the
Schulz approach [7,8], and the Effective Public Health Practice
Project Quality Assessment Tool (EPHPP) [9]. Hartling et al.
demonstrated low correlation and varied inter-rater agreements
between the ROB tool assessments and the Jadad scale [7,8].
Other reviews of SRs and MAs published in Chinese journals
have identified problems with methodological or reporting quality,
however, these studies failed to pay attention to use of the ROB
tool in their reviews [10–12].
The QUOROM statement [13] and the updated version of the
PRISMA statement [14] encourage use of the terms systematic
review or meta-analysis in titles of such studies, in order to
maximize search success. Among the reviews we identified, most
included these terms in their titles, however, nine SRs or MAs
failed to use these terms in their titles in Chinese. In addition, most
reviews did not declare whether a conflict of interest existed or not,
which is a potential threat to validity.
Although acupuncture belongs to the domain of TCM, most
SRs and MAs focus on ‘‘western disease’’ rather than ‘‘TCM
syndrome’’ as their diagnostic criteria. Consequently, TCM
practitioners may find it difficult to understand and apply evidence
from such publications in their clinical practice because TCM
places more emphasis on syndromes rather than on western
disease classifications. Therefore, some researchers propose using
both western disease and TCM syndrome in their diagnostic
criteria in studies of TCM. This is an interesting issue worthy of
serious discussion but it is beyond the scope of this paper.
Many instruments exist for assessing the ‘‘quality’’ of RCTs.
While 25 scales and nine checklists were published prior to 1994
Table 2. The use of numerous tools in studies.
Assessment tools 2000–2008 y (n=36) 2009–2011.3 y (n=69)
Cochrane Handbook version 4 7 25
Cochrane Handbook version 5 - 13
Cochrane Handbook (version not reported) 5 13
Jadad scale 12 (11+1*) 40 (15+25*)
Juni 3 1
PED pro 1 0
No mention assessment tool 7 2 (1+1
#)
Others 2 0
*The number of reviews that applied both the Jadad scale and another.
#No use any assessment tool.
doi:10.1371/journal.pone.0028130.t002
Table 3. Reporting of the six domains in the ROB tool in SRs and MAs after 2009.
ROB tool’s domains
Systematic reviews
(n=50)
Meta-analyses
(n=13)
Others titles
(n=6)
Subtotal
(n=69)
Sequence generation 48 13 6 67
Allocation concealment 42 9 5 56
Blindness 49 13 6 68
Blinding participants 1 1 0 2
Blinding healthcare providers 0 1 0 1
Blinding outcome assessors 2 0 0 2
Blinding data analysts 2 0 0 2
Incomplete outcome data 7 1 0 8
Loss of follow-up 43 7 6 56
Intention-to-treat (ITT) analysis 14 4 1 19
Selective outcome reporting. 4 0 0 4
Other potential sources of bias 4 0 0 4
Using ROB graph/summary 2 0 0 2
Reported verbatim quotes 0 0 0 0
doi:10.1371/journal.pone.0028130.t003
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[2,4,17–20] or both methodological quality and reporting quality
[21–24] have since been proposed. Despite the abundance of such
instruments, assessment tools specifically for evaluating acupunc-
ture RCTs are rare [23]. In addition, some items of these
instruments are not directly related to internal validity. For
example, whether a power calculation was done or not relates to
the precision of the results rather than internal validity [2]. In our
study, we concentrated on tools that focused on internal validity.
We found that the Cochrane Handbook and the Jadad scale
were often chosen by Chinese reviewers. Although, the Jadad scale
has been popular for many years, using the Cochrane Collabo-
ration ROB tool instead of the Jadad scale should be recom-
mended when performing SRs and MAs. There are several core
reasons for this recommendation: 1) the Jadad scale is based on
reporting quality rather than actual RCT conduct [4]; 2) while the
Jadad scale focuses on randomization, double blinding, withdraw-
als or dropouts, we believe these criteria are insufficient to assess
the internal validity of RCTs; 3) the Jadad scale tends to
overestimate treatment effects because it ignores allocation
concealment [25] and selective outcome reporting [26,27], which
are very important to overall assessment of ROB; and 4) the term
‘‘double blind’’ is incomplete and lacks specificity for assessing
‘‘blinding’’ because it is not clear who is blinded [28].
We found that most Chinese SRs and MAs were written
according to the Cochrane Collaboration’s Handbook. The
Cochrane Handbook is frequently updated, the most recent being
version 5.1.0, published in March 2011 [2]. Although many scales
and tools are available for assessing methodological quality of
RCTs, the new version of the Cochrane handbook recommends
that a specific ROB tool be used assess the risk of bias in each
included study. It is not uncommon that authors of SRs and MAs
use the terms ‘‘methodological quality’’ and ‘‘risk of bias’’
interchangeably. The term ‘‘bias’’ indicates a systematic error or
deviation from the truth in a study’s results or inferences [2].
Assessing ROB is to directly assess the extent that the results of
included studies should be believed [2]. But not all parts of quality
assessment have direct implications for ROB. Therefore, ROB is
recommended for assessing ‘‘bias’’ instead of methodological
quality, because ‘‘bias’’ may be different from ‘‘quality’’. For
example, blinding is difficult or impossible for some interventions,
such as surgery or Chinese herbal medicine. In these cases, the risk
from lack of blinding may affect the trial’s validity, however, it may
be inappropriate to score these studies as ‘‘low quality’’ [2].
The Cochrane ROB tool was recommended in Cochrane
handbook version 5.0.1, although ‘selective reporting’ and ‘other
potential sources of bias’ were mentioned in Handbook 4.2.6. Few
of the reviews we identified [18.8% (13/69)] reported that they
used Cochrane Handbook 5 and only three of these also used all 6
domains. One review reported use of Cochrane Handbook 4.2.6
and also described the selective outcome reporting bias and the
other potential sources of bias. Most SRs and MAs reported
information about sequence generation, allocation concealment,
blindness, and incomplete outcome data, however, major reviews
ignored selective outcome reporting and other potential sources of
bias. These studies that lack analysis of selective outcome reporting
and other sources of bias have performed incomplete ROB
assessment. Although baseline imbalance was described, many
SRs and MAs failed to analyze the influence of other sources of
bias. None of the SRs and MAs in our study analyzed early
stoppage, conflict of interest, or other factors that are other
potential threats to validity. Some of the SRs and MAs that
reported using Cochrane Handbook 5 in their methods, actually
used version 4 in their results. It is easy to mislead a reader because
most clinicians may not know the differences between Cochrane
Handbook 4 and Handbook 5.
With regards to blinding, we noticed that most reviews failed to
describe the blinding process in detail. In a clinical trial, different
types of personnel can be blinded, such as participants, healthcare
providers, outcome assessors, and data analysts. If we do not know
which types of personnel were blinded, it is difficult to accurately
judge which bias (performance bias or measurement bias) may
have occurred. In addition, use of the term ‘‘double blind’’ is
ambiguous and authors often fail to state exactly who was blinded
[28]. Some people assume ‘‘double blind’’ means that patients and
clinicians were blinded, however, some authors reported ‘‘double
blind’’, when patients and outcome assessors were blinded.
Furthermore, for subjective outcomes, blinding outcome assessors
is more important than blinding clinicians in order to avoid
measurement bias.
While most reviews provided details of loss to follow-up
(attrition/drop-out) and ITT analyses, few mentioned the term
‘‘incomplete outcome data’’. We recommend that future reviews
include information about incomplete outcome data, not only the
amount and distribution of drop-outs across study groups but also
the reasons for outcomes being absent. This would help reviewers
assess the risk of attrition bias.
The ‘‘risk of bias summary’’ figure was provided in few reviews.
Reasons for this may be that reviewers are not be aware of this
requirement or that journals may require specific layout
specifications that authors are unable to comply with.
In order to improve assessment of risk of bias, we recommend
that the most recent version of the Cochrane ROB tool be used by
SR and MA authors. Reviewers should continue to update their
knowledge according to the latest Cochrane Collaboration
Handbook versions and other developing methodology and to
clearly state which version of the tool or handbook was used in
their reviews.
There are several limitations in the study. We included SRs and
MAs that primarily focused on acupuncture. Those reviews
involving acupuncture as a secondary intervention were excluded.
We only selected SRs and MAs published in Chinese journals and
therefore our results are only applicable to those journals. In
addition, we did not analyze internal validity and inter-rater
agreements between the ROB tool assessments and the Jadad scale
or other assessment tools.
In conclusion, the Cochrane Handbook and the Jadad scale
were the risk of bias or quality assessment instruments most
commonly used by Chinese authors of systematic reviews and
meta-analyses of acupuncture. In reviews published after 2008 in
Chinese journals, Cochrane ROB tools were not always used. In
cases where a Cochrane ROB tool was used, reporting was
sometimes incomplete.
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